[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].

Autor: Vorobyev VI; Botkin City Clinical Hospital., Gemdzhian EG; National Research Center for Hematology., Fedorova LV; Pavlov First Saint Petersburg State Medical University., Mikhailova NB; Pavlov First Saint Petersburg State Medical University., Ilyasov RK; Efetov Crimean Republican Oncological Clinical Dispensary., Kaleikina LP; Republican Oncological Dispensary., Trubyakova OS; Vladimir City Clinical Hospital №5., Kaplanov KD; Botkin City Clinical Hospital., Melnichenko EV; Novosibirsk Hematology Center., Martynova EV; Krasnoyarsk Regional Clinical Hospital., Yakovleva EP; Regional Clinical Hospital., Li OY; Sakhalin Regional Clinical Hospital., Tarasenko EV; Pirogov City hospital №1., Chumakova EP; Perm Regional Clinical Hospital., Bulieva NB; Regional Clinical Hospital of the Kaliningrad Region., Nesterova ES; National Research Center for Hematology., Margolin OV; National Research Center for Hematology., Zherebtsova VA; Botkin City Clinical Hospital., Butaev LS; Botkin City Clinical Hospital., Ptushkin VV; Botkin City Clinical Hospital.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2021 Jul 23; Vol. 93 (7), pp. 770-777. Date of Electronic Publication: 2021 Jul 23.